1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Zenith Capital Corp.

Zenith Capital Corp.

ZHCLF
Zenith Capital Corp.US flagOther OTC
0.05
USD
- -
- -
7.99MMarket Cap
Zenith Capital Corp.
ZHCLF
(Other OTC)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
FRC
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
Tangible Book Value per Share
131
131
130
134
136
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Lakefront Biotherapeutics (GLPGF)
Radiopharm Theranostics Limited (RADX)
Amplia Therapeutics Limited (ATX.AX)
Equillium, Inc. (EQ)
Genomic Valley Biotech Ltd (GVBL.BO)
Peptron, Inc. (087010.KQ)
Business
Zenith Capital Corp. (ZHCLF) is a biotechnology investment company that operates through its wholly-owned subsidiary Zenith Epigenetics Ltd., a clinical-stage biotechnology firm focused on the discovery, development and commercialization of bromodomain and extra-terminal (BET) inhibitors for oncology indications and other disorders with significant unmet medical needs; its lead product candidate ZEN-3694, a selective BET inhibitor, is in Phase 2 clinical trials for metastatic castration-resistant prostate cancer (mCRPC) in combination with other agents and for metastatic triple-negative breast cancer, with additional evaluation in other solid tumors; the company advances novel BET inhibitor combinations with targeted therapies including those from partners. Zenith Capital maintains research and development collaborations with the National Cancer Institute, licensing agreements with Newsoara Biopharma for ZEN-3694 in greater China, and clinical development partnerships with Astellas Pharma and Pfizer Inc. for specific oncology programs. In recent developments, ZEN-3694 received U.S. FDA Orphan Drug Designation, and the company entered a commercialization acceleration agreement with Cencora (formerly AmerisourceBergen) to support potential market entry. Founded in 2013 and headquartered in Calgary, Alberta, Canada, with key operations and a development team based in San Francisco, California, Zenith Capital targets global markets in North America, Europe and Asia through its partnerships and licensing arrangements.